Sarah Blondell

Sarah Blondell is the VP of Clinical Operations at Eleusis. Since joining the Eleusis team in 2014, Sarah has been instrumental in the successful completion of the company’s clinical trials of LSD, and is now leading the clinical development of the Eleusis drug candidate pipeline. Sarah has over 25 years clinical development experience in the pharmaceutical industry and has led global clinical trials for several market leading psychoactive medicines.

Sarah has previously directed clinical trials at Lundbeck, i3 Research (Syneos) and Quintiles (IQVIA). Sarah received her BSc (Hons) in Biological Sciences and Psychology from the University of Leicester, UK and her MSc in Clinical Pharmacology from the University of Aberdeen, UK.